Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancerEzra E.W. Cohen, J.-P. Machiels, Lisa Licitra et al.|Annals of Oncology|2017Cited by 80
Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular EntityAleix Prat, Javier Cortés, Paolo Nucíforo et al.|Scientific Reports|2013Cited by 56
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trialPaul M. Clément, Jan B. Vermorken, Thomas Gauler et al.|Annals of Oncology|2016Cited by 45
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckBarbara Burtness, Robert I. Haddad, José Dinis et al.|JAMA Oncology|2019Cited by 43